The mammalian target of rapamycin (mTOR) pathway integrates nutrient availability, growth factor signaling, lysosomal status, and cellular energy balance to regulate protein synthesis, autophagy, and stress adaptation. In neurodegeneration, abnormal mTOR signaling is critical because it shapes proteostasis, synaptic plasticity, lysosomal function, and inflammatory responses across neurons and glia.
flowchart TB
subgraph Inputs[" upstream Inputs to mTORC1"]
A["Growth Factors<br/>IGF-1, BDNF"] --> B["PI3K"]
B --> C["AKT"]
C --> D["TSC1/2"]
D -->|"Inhibition"| E["RHEB"]
F["Amino Acids<br/>Leucine"] --> G["Rag GTPases"]
G --> H["mTORC1<br/>Localization"]
I["Energy Stress<br/>ATP depletion"] --> J["AMPK"]
J -->|"Activation"| K["TSC2"]
K -->|"Activation"| D
J -->|"Phosphorylation"| L["Raptor"]
L -->|"Inhibition"| M["mTORC1"]
M --> N["Lysosomal<br/>Surface"]
end
subgraph mTORC1_Active["mTORC1 Active Complex"]
OmTOR["OmTOR<br/>Raptor<br/>mLST8<br/>PRAS40"]
end
subgraph Downstream[" mTORC1 Downstream Targets"]
O --> P["p70S6K"]
O --> Q["4E-BP1"]
P -->|"Phosphorylation"| R["ribosomal<br/>protein S6"]
Q -->|"Phosphorylation"| S["eIF4E<br/>Release"]
R --> T["Protein<br/>Synthesis"]
S --> T
O --> U["ULK1"]
U -->|"Ser757<br/>Phosphorylation"| V["Autophagy<br/>Inhibition"]
O --> W["TFEB"]
W -->|"Phosphorylation"| X["Cytoplasmic<br/>Retention"]
X --> V
O --> Y["SREBP"]
Y --> Z["Lipid<br/>Synthesis"]
end
subgraph mTORC2["mTORC2 Complex"]
AA["Growth Factors"] --> BB["mTORC2<br/>Rictor<br/>mLST8"]
BB --> CC["AKT"]
CC -->|"Ser473<br/>Phosphorylation"| DD["Full AKT<br/>Activation"]
DD --> EE["Cell Survival<br/>AKT Signaling"]
BB --> FF["PKCα"]
FF --> GG["Cytoskeletal<br/>Organization"]
BB --> HH["SGK1"]
HH --> II["Ion Transport<br/>Cell Survival"]
end
subgraph Disease[" Neurodegenerative Disease Relevance"]
T --> JJ["Synaptic<br/>Plasticity"]
V --> KK["Impaired<br/>Autophagy"]
KK --> LL["Aggregate<br/>Accumulation"]
LL --> MM["Amyloid-β<br/>Tau<br/>α-Synuclein"]
JJ --> NN["Synaptic<br/>Dysfunction"]
MM --> OO["AD/PD<br/>Pathology"]
end
style O fill:#c8e6c9,stroke:#333,stroke-width:2px
style M fill:#FFB6C1,stroke:#333,stroke-width:2px
style V fill:#FF6B6B,stroke:#333,stroke-width:2px
style KK fill:#FF6B6B,stroke:#333,stroke-width:2px
style LL fill:#FF6B6B,stroke:#333,stroke-width:2px
style OO fill:#FF6B6B,stroke:#333,stroke-width:2px
¶ mTORC1 Structure and Function
The mTOR complex 1 (mTORC1) consists of:
- mTOR — the catalytic core serine/threonine kinase
- Raptor (regulatory-associated protein of mTOR) — scaffolds substrate recruitment
- mLST8 — supports kinase activity
- PRAS40 and Deptor — regulatory subunits that inhibit activity under certain conditions
mTORC1 functions as a nutrient/energy sensor and promotes anabolic processes:
- Protein synthesis via p70S6K and 4E-BP1 phosphorylation
- Lipid synthesis through SREBP activation
- Ribosome biogenesis
- Autophagy suppression via ULK1 phosphorylation and TFEB inhibition
¶ mTORC2 Structure and Function
The mTOR complex 2 (mTORC2) consists of:
- mTOR — the catalytic core
- Rictor (rapamycin-insensitive companion of mTOR) — defining subunit
- mLST8 — shared with mTORC1
- Protor1/2 and Deptor — regulatory subunits
mTORC2 regulates:
- AKT full activation through Ser473 phosphorylation
- PKCα phosphorylation and cytoskeletal organization
- SGK1 activation for ion transport and cell survival
mTORC1 is a central negative regulator of autophagy. When active:
-
ULK1 phosphorylation: mTORC1 phosphorylates ULK1 at Ser757, disrupting the ULK1-AMPK interaction and inhibiting autophagy initiation
-
TFEB inhibition: mTORC1 phosphorylates TFEB, retaining it in the cytoplasm and preventing transcription of lysosomal and autophagy genes
-
ATG proteins: mTORC1 signaling modulates the activity of ATG proteins involved in autophagosome formation
In neurodegeneration, mTORC1 hyperactivation contributes to:
- Impaired autophagic flux
- Accumulation of protein aggregates
- Lysosomal dysfunction
mTORC1 regulates translation through two main effectors:
- Phosphorylation of p70S6K activates it
- p70S6K then phosphorylates ribosomal protein S6, enhancing translation of 5'TOP mRNAs
- Promotes translation of components needed for synaptic plasticity
- Phosphorylation of 4E-BP1 releases eIF4E
- Enables formation of the eIF4F translation initiation complex
- Facilitates cap-dependent translation
Dysregulated protein synthesis contributes to synaptic dysfunction in Alzheimer's disease and Parkinson's disease.
mTOR signaling is essential for synaptic plasticity through:
- Local translation at synapses: mTORC1 activity in dendritic spines regulates synthesis of synaptic proteins
- AMPA receptor trafficking: mTORC2-AKT signaling modulates AMPA receptor insertion
- Long-term potentiation (LTP): Required for the protein synthesis-dependent late phase of LTP
- Memory consolidation: mTOR-dependent translation in the hippocampus is necessary for memory formation
However, excessive mTOR activity can impair synaptic function by:
- Promoting abnormal protein synthesis
- Inhibiting autophagy needed for synaptic vesicle recycling
- Contributing to dendritic spine abnormalities observed in AD
In Alzheimer's disease, mTOR dysregulation manifests as:
- Hyperactivity: mTOR signaling is elevated in AD brains, contributing to amyloid accumulation and impaired autophagy
- Tau pathology: mTOR phosphorylates tau at multiple sites; hyperactivation promotes tau aggregation and impairs tau clearance
- Synaptic failure: Abnormal translation regulation contributes to synaptic protein loss
- Therapeutic targeting: mTOR inhibitors show promise in preclinical AD models but must balance benefits against potential cognitive side effects
In Parkinson's disease and related synucleinopathies:
- α-Synuclein clearance: mTORC1 inhibition enhances autophagic clearance of α-synuclein
- Lysosomal function: mTOR regulates lysosomal biogenesis; dysregulation contributes to impaired protein clearance
- Mitochondrial quality control: mTOR affects mitophagy through ULK1 regulation
- LRRK2 interaction: LRRK2 mutations affect mTOR signaling
| Regulator |
Mechanism |
Effect on mTORC1 |
| PI3K/AKT |
AKT phosphorylates TSC2, PRAS40 |
Activation |
| AMPK |
Phosphorylates TSC2, Raptor |
Inhibition |
| RHEB |
Direct activator when GTP-bound |
Activation |
| Amino Acids |
Rag GTPases recruit mTORC1 to lysosome |
Activation |
| TSC1/2 |
Integrates multiple signals via Rheb |
Inhibition |
Modulating mTOR for neurodegenerative disease therapy requires careful consideration:
- Enhanced autophagy and aggregate clearance
- Reduced tau phosphorylation and aggregation
- Improved lysosomal function
- Impaired synaptic plasticity and memory consolidation
- Potential interference with neuronal survival pathways
- Context-dependent effects (early vs. late disease)
- Rapamycin/rapalogs: Allosteric mTORC1 inhibitors
- ATP-competitive inhibitors: Target both mTORC1 and mTORC2
- Combination therapy: mTOR inhibition with autophagy induction